220 related articles for article (PubMed ID: 37193673)
1. Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections.
Weil-Olivier C; Salisbury D; Navarro-Alonso JA; Tzialla C; Zhang Y; Esposito S; Midulla F; Tenenbaum T
Hum Vaccin Immunother; 2023 Dec; 19(1):2209000. PubMed ID: 37193673
[TBL] [Abstract][Full Text] [Related]
2. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies.
Lee Mortensen G; Harrod-Lui K
Expert Rev Vaccines; 2022 Oct; 21(10):1523-1531. PubMed ID: 35929971
[TBL] [Abstract][Full Text] [Related]
3. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
Sparrow E; Adetifa I; Chaiyakunapruk N; Cherian T; Fell DB; Graham BS; Innis B; Kaslow DC; Karron RA; Nair H; Neuzil KM; Saha S; Smith PG; Srikantiah P; Were F; Zar HJ; Feikin D
Vaccine; 2022 Jun; 40(26):3506-3510. PubMed ID: 35184927
[TBL] [Abstract][Full Text] [Related]
4. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Jones JM; Fleming-Dutra KE; Prill MM; Roper LE; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Meyer S; Long SS; McMorrow ML
MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(34):920-925. PubMed ID: 37616235
[TBL] [Abstract][Full Text] [Related]
5. Direct long-acting antibodies: updating the language of RSV prevention to reflect the evolution of mAbs.
Lopalco PL; Esposito S; Martinón-Torres F; ; Checcucci Lisi G; Chung-Delgado K; Davidson B; Evans S; Patel A; Fellingham C; Pounds B; Harris C; Mukherjee T
J Prev Med Hyg; 2023 Dec; 64(4):E377-E381. PubMed ID: 38379744
[TBL] [Abstract][Full Text] [Related]
6. Passive and active immunization against respiratory syncytial virus for the young and old.
Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
[TBL] [Abstract][Full Text] [Related]
7. Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis.
Jacque E; Chottin C; Laubreton D; Nogre M; Ferret C; de Marcos S; Baptista L; Drajac C; Mondon P; De Romeuf C; Rameix-Welti MA; Eléouët JF; Chtourou S; Riffault S; Perret G; Descamps D
Front Immunol; 2021; 12():683902. PubMed ID: 34163482
[TBL] [Abstract][Full Text] [Related]
8. Immunization, not vaccination: monoclonal antibodies for infant RSV prevention and the US vaccines for children program.
Sevilla JP
J Med Econ; 2023; 26(1):991-997. PubMed ID: 37498791
[TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
[TBL] [Abstract][Full Text] [Related]
10. Understanding New Recommendations for Respiratory Syncytial Virus Prevention in Pregnancy.
Horgan R; Hughes BL; Waller J; Hage Diab Y; Saade G
Obstet Gynecol; 2024 Apr; 143(4):484-490. PubMed ID: 38330405
[TBL] [Abstract][Full Text] [Related]
11. Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood.
Scotta MC; Stein RT
J Pediatr (Rio J); 2023; 99 Suppl 1(Suppl 1):S4-S11. PubMed ID: 36402228
[TBL] [Abstract][Full Text] [Related]
12. Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.
Giersing BK; Karron RA; Vekemans J; Kaslow DC; Moorthy VS
Vaccine; 2019 Nov; 37(50):7355-7362. PubMed ID: 28302410
[TBL] [Abstract][Full Text] [Related]
13. Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus.
Verwey C; Madhi SA
BioDrugs; 2023 May; 37(3):295-309. PubMed ID: 37097594
[TBL] [Abstract][Full Text] [Related]
14. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants.
Rainisch G; Adhikari B; Meltzer MI; Langley G
Vaccine; 2020 Jan; 38(2):251-257. PubMed ID: 31740097
[TBL] [Abstract][Full Text] [Related]
15. Number needed to immunize to prevent RSV with extended half-life monoclonal antibody.
Finelli L; Choi Y; Goldstein E
Vaccine; 2020 Jul; 38(34):5474-5479. PubMed ID: 32600912
[TBL] [Abstract][Full Text] [Related]
16. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
Atwell JE; Lutz CS; Sparrow EG; Feikin DR
Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
[TBL] [Abstract][Full Text] [Related]
17. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
Ektare V; Lang J; Choi Y; Finelli L
Vaccine; 2022 Oct; 40(42):6064-6073. PubMed ID: 36096968
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
Munoz FM
Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
[TBL] [Abstract][Full Text] [Related]
20. Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.
Zheng Z
Yale J Biol Med; 2022 Jun; 95(2):293-300. PubMed ID: 35782467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
